CA2352487A1 - Utilisation de capsules contenant un ou plusieurs antigenes, pour la prevention et/ou le traitement de maladies auto-immunes - Google Patents

Utilisation de capsules contenant un ou plusieurs antigenes, pour la prevention et/ou le traitement de maladies auto-immunes Download PDF

Info

Publication number
CA2352487A1
CA2352487A1 CA002352487A CA2352487A CA2352487A1 CA 2352487 A1 CA2352487 A1 CA 2352487A1 CA 002352487 A CA002352487 A CA 002352487A CA 2352487 A CA2352487 A CA 2352487A CA 2352487 A1 CA2352487 A1 CA 2352487A1
Authority
CA
Canada
Prior art keywords
capsules
antigenic substances
taste
auto
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002352487A
Other languages
English (en)
Inventor
Hans-Jurgen Hahn
Hans-Werner Heinrich
Udo Meyer
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bioserv AG
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2352487A1 publication Critical patent/CA2352487A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0008—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Emergency Medicine (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

L'invention concerne l'utilisation de capsules, notamment de microcapsules, contenant un ou plusieurs antigènes, pour créer un état d'immunotolérance dans des organismes et pour prévenir et/ou traiter des maladies auto-immunes.
CA002352487A 1998-11-27 1999-11-19 Utilisation de capsules contenant un ou plusieurs antigenes, pour la prevention et/ou le traitement de maladies auto-immunes Abandoned CA2352487A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE19854749A DE19854749A1 (de) 1998-11-27 1998-11-27 Verwendung von Kapseln, die eine oder mehrere antigene Substanzen enthalten, zur Prävention und/oder Behandlung von Autoimmunerkrankungen
DE19854749.8 1998-11-27
PCT/DE1999/003687 WO2000032168A1 (fr) 1998-11-27 1999-11-19 Utilisation de capsules contenant un ou plusieurs antigenes, pour la prevention et/ou le traitement de maladies auto-immunes

Publications (1)

Publication Number Publication Date
CA2352487A1 true CA2352487A1 (fr) 2000-06-08

Family

ID=7889209

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002352487A Abandoned CA2352487A1 (fr) 1998-11-27 1999-11-19 Utilisation de capsules contenant un ou plusieurs antigenes, pour la prevention et/ou le traitement de maladies auto-immunes

Country Status (6)

Country Link
EP (1) EP1135107A1 (fr)
JP (1) JP2002531391A (fr)
AU (1) AU1856200A (fr)
CA (1) CA2352487A1 (fr)
DE (1) DE19854749A1 (fr)
WO (1) WO2000032168A1 (fr)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10135494A1 (de) 2001-07-20 2003-11-06 Jobst Krauskopf Verwendung eines Lactatsalzes zur Behandlung und Prophylaxe der Athereosklerose
DE10331202A1 (de) 2003-07-10 2005-03-31 S.K. Enterprise Gmbh Verwendung von Molkenpermeat zur Behandlung des Metabolischen Syndroms
DE102006036285A1 (de) 2006-08-03 2008-02-07 "S.U.K." Beteiligungs Gmbh Fraktionen aus Molkepermeat und deren Verwendung zur Prävention und Therapie des Typ-2 Diabetes und des Metabolischen Syndroms

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5843445A (en) * 1987-06-24 1998-12-01 Autoimmune, Inc. Method of treating rheumatoid arthritis with type II collagen
US5427935A (en) * 1987-07-24 1995-06-27 The Regents Of The University Of Michigan Hybrid membrane bead and process for encapsulating materials in semi-permeable hybrid membranes
AU664561B2 (en) * 1991-06-21 1995-11-23 University Of Cincinnati, The Orally administrable therapeutic proteins and method of making
DE19644343A1 (de) * 1996-10-25 1998-04-30 Privates Inst Bioserv Gmbh Geschmacksneutrale Mikrokapseln, Verfahren zu ihrer Herstellung sowie ihre Verwendung
US5948407A (en) * 1997-03-19 1999-09-07 Shire Laboratories Inc. Oral induction of tolerance to parenterally administered non-autologous polypeptides

Also Published As

Publication number Publication date
WO2000032168A1 (fr) 2000-06-08
JP2002531391A (ja) 2002-09-24
DE19854749A1 (de) 2000-05-31
AU1856200A (en) 2000-06-19
EP1135107A1 (fr) 2001-09-26

Similar Documents

Publication Publication Date Title
AU2011100404B4 (en) Methods for enhancing palatability of compositions for animal consumption
US5645851A (en) Product for alleviating the symptons of arthritis in mammals
Gevaert et al. Fish hydrolysates: A regulatory perspective of bioactive peptides
Lin et al. Hypocholesterolemic effect of compounded freshwater clam protein hydrolysate and Gracilaria
WO2008120797A1 (fr) Activateur d'ampk
Ayman et al. Dietary chitosan oligosaccharides improves health status in broilers for safe poultry meat production
CA2441192C (fr) Utilisation de lysine pour la prevention ou le traitement des maladies induites par le stress
JP2018130130A (ja) 鶏胸肉由来のプラズマローゲン組成物とこれを含有して成る健常被験者の言語と状況に関連した物忘れがないようにするための食品組成物
CA2352487A1 (fr) Utilisation de capsules contenant un ou plusieurs antigenes, pour la prevention et/ou le traitement de maladies auto-immunes
JP3602586B2 (ja) 餌料用組成物
Schmidt et al. The nutritive value of egg by‐products and their potential bactericidal activity: in vitro and in vivo studies
JP2010528651A (ja) 家禽の体重増量を向上させるための手段および方法
Semba The vitamin A and mortality paradigm: past, present, and future
Lv et al. Growth performance and meat quality of broiler chickens supplemented with chicken-specific Lactobacillus CSL-13 in drinking water
RU2043737C1 (ru) Композиция мясорастительного продукта для диетического и лечебно-профилактического питания
JPH07194314A (ja) カルシウム吸収促進性水溶性画分、それを含有する組成物およびカルシウム吸収促進用添加剤
Burin Junior Intestinal integrity, oxidative stress, and immune competence of broilers exposed to heat stress and supplemented with Zn amino acid complex
HORIKAWA et al. Effects of dietary gizzerosine on calcium content in the femur of chicks
CN118000352A (zh) 一种用于调理宠物犬猫肠道功能的保健食品及其制备方法
JP6251427B2 (ja) 魚類アレルギー耐性獲得用食品組成物
JP6368390B2 (ja) 魚類アレルギー耐性獲得の評価方法
JPH0669A (ja) 肝障害患者に有効な組成物
CN115736110A (zh) 酶解流质宠物罐头及其制备方法
Ogboko The effect of zinc bacitracin on the physiology of broilers fed plant and animal protein diets
ALI et al. THE USE OF PROBIOTIC AND PROTEASE ENZYME IN LAYERS

Legal Events

Date Code Title Description
FZDE Dead